Author:
Almomen Aliyah,Jarboe Elke A.,Dodson Mark K.,Peterson C. Matthew,Owen Shawn C.,Janát-Amsbury Margit M.
Funder
Faculty and Creative grant and Department of Obstetrics and Gynecology at the University of Utah
National Cancer Institute
The Huntsman cancer institute’s women’s disease-oriented teams research funding
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference61 articles.
1. Ho JC, Allen PK, Jhingran A, Westin SN, Lu KH, Eifel PJ, et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015;139(1):40–6.
2. Altman AD, Ferguson SE, Atenafu EG, Kobel M, McAlpine JN, Panzarella T, et al. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. Gynecol Oncol. 2015;139(2):268–74.
3. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol, Biomarkers Prev: Publ Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2002;11(12):1531–43.
4. Felix AS, Scott McMeekin D, Mutch D, Walker JL, Creasman WT, Cohn DE, et al. Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial. Gynecol Oncol. 2015;139(1):70–6.
5. Siegel L, Miller K, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献